Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Inherited Metabolic Disease
Published in: Journal of Inherited Metabolic Disease 5/2016

01-09-2016 | Highlights

News and views

Author: Peter Witters

Published in: Journal of Inherited Metabolic Disease | Issue 5/2016

Login to get access

Excerpt

In developing and producing drugs for orphan diseases, there is an obvious contradiction between the rarity of the disease and possible financial gains associated with drug development and production if drug prices are kept low. Modalities aiming to tackle this contradiction include orphan drug legislation and the enthusiasm of drug developers. …
Literature
Morel T, Lhoir A, Picavet E, Mariz S, Sepodes B, Llinares J et al (2016) Regulatory watch: the orphan drug pipeline in Europe. Nat Rev Drug Discov 15:376CrossRefPubMed
Metadata
Title
News and views
Author
Peter Witters
Publication date
01-09-2016
Publisher
Springer Netherlands
Published in
Journal of Inherited Metabolic Disease / Issue 5/2016
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI
https://doi.org/10.1007/s10545-016-9964-7

Other articles of this Issue 5/2016

Journal of Inherited Metabolic Disease 5/2016 Go to the issue

Original Article

Expanding the molecular diversity and phenotypic spectrum of glycerol 3-phosphate dehydrogenase 1 deficiency

Letter

On the origin of 3-methylglutaconic acid in disorders of mitochondrial energy metabolism

Erratum

Erratum to: Untargeted metabolomic analysis for the clinical screening of inborn errors of metabolism

Original Article

Age at disease onset and peak ammonium level rather than interventional variables predict the neurological outcome in urea cycle disorders

Erratum

Erratum to: ALG6-CDG: a recognizable phenotype with epilepsy, proximal muscle weakness, ataxia and behavioral and limb anomalies

Original Article

Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits